Latest News and Press Releases

Chicago, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The global bio-vanillin market was valued at US$ 290.7 billion in 2024 and is expected to reach US$ 454.9 million by 2033, growing at a CAGR of 5.1%...

Ottawa, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The global stem cell therapy market size was estimated at USD 490 million in 2024 and is forecasted to reach approximately USD 4,777.4 million by 2034,...

Chicago, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The global breastfeeding accessories market was valued at US$ 1.9 billion in 2024 and is expected to reach US$ 4.2 billion by 2033, growing at a CAGR of...

Austin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- AI in Diagnostics Market Size & Growth Analysis According to SNS Insider, the global Ai In Diagnostics Market was valued at USD 1.62 billion in 2024...

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform...

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide...

Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for...

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on...

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,...

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System.

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation...

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air...

There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by...

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated...

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage...

Austin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prefilled Syringes Market Size & Growth Analysis SNS Insider reported that global prefilled syringes market size was valued at USD 7.31 billion in...

MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

•  Clinical data demonstrated administration of AGA2115 drove dose-dependent increases in bone mineral density •  The Company and collaborators also presented data from non-human primate and mouse...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI...

5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures...

TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will...

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative...

Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease...

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated...

124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with...

iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 ...

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK...

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support...

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Austin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Anti-reflective Coatings Market Size & Growth Analysis: “According to SNS Insider, the Anti-reflective Coatings Market Size was valued at USD 5.78...

- Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG...

Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures,...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The CE Mark certification allows marketing for both clinic and...

NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options If you purchased or...

Lawsuit alleges Replimune overstated IGNYTE trial prospects despite flaws; FDA deemed trial inadequate, causing investor losses.

Capricor misled investors on deramiocel’s approval prospects; FDA rejected its BLA, citing lack of efficacy data, causing shares to fall 33%.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or...

Salt Lake City, Sept. 06, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only and does not provide medical advice. Some links in this article may be promotional affiliate...

New York, Sept. 06, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and...

Los Angeles, Sept. 06, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment...

- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0%...

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and...